Exploring how farnesol affects gut health and inflammation in multiple sclerosis
Therapeutic Mechanisms of Farnesol in Modulating Gut Dysbiosis and Neuroinflammation in Multiple Sclerosis
This study is looking at how a natural compound called farnesol might help improve gut health and reduce inflammation in people with multiple sclerosis, to see if it can make managing MS symptoms easier and improve overall well-being.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boise State University NIH-funded |
| Lab location | 1 site (Boise, United States) |
| Project ID | NIH-11116456 on NIH RePORTER |
What this research studies
This research investigates the effects of farnesol, a natural compound, on gut health and inflammation in individuals with multiple sclerosis (MS). The study aims to understand how farnesol can influence gut microbiota and the integrity of the intestinal barrier, which may play a role in the progression of MS. By examining these mechanisms, the research seeks to identify potential therapeutic benefits of farnesol in managing MS symptoms and improving patient outcomes. Participants may be involved in assessments of gut health and inflammation levels throughout the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis who may experience gut dysbiosis and neuroinflammation.
Not a fit: Patients with other autoimmune diseases unrelated to multiple sclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for managing multiple sclerosis by improving gut health and reducing neuroinflammation.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting gut health and inflammation in autoimmune diseases, suggesting potential for success in this area.
Where this research is happening
Boise, United States
- Boise State University — Boise, United States (Active)
Researchers
- Principal investigator: Ochoa-Reparaz, Javier — Boise State University
- Study coordinator: Ochoa-Reparaz, Javier
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.